PortViewPortView
Kamada logo

Kamada (KMDA) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$8.36-0.24%
1-year price historyRange $6.60 – $9.31
52-week range$8.36
$6.50$9.35

What Kamada does

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Key metrics

Market cap
$482.32M
P/E (TTM)
22.00
EPS (TTM)
$0.38
Beta
0.15
Dividend yield
5.02%
Revenue / share
$3.31
50-day avg
$7.43
200-day avg
$7.81
52-week high
$9.35
52-week low
$6.50
CEO
Amir London

ETFs linked to KMDA

Broad-market and Healthcare sector ETFs an investor holding Kamada is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KMDA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze KMDA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Kamada?
Kamada trades under the ticker KMDA on NASDAQ.
Which exchange is KMDA listed on?
KMDA is listed on NASDAQ.
What sector does Kamada operate in?
Kamada is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze KMDA in a portfolio?
PortView shows KMDA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.